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Background.The brain’s inflammatory response to the infecting pathogen determines the outcome of bacterial meningitis (BM), for
example, the associatedmortality and the extent of brain injury.The inflammatory cascade is initiated by the presence of bacteria in
the cerebrospinal fluid (CSF) activating resident immune cells and leading to the influx of blood derived leukocytes. To elucidate the
pathomechanisms behind the observed difference in outcome between different pathogens, we compared the inflammatory profile
in the CSF of patients with BM caused by Streptococcus pneumonia (𝑛 = 14), Neisseria meningitidis (𝑛 = 22), and Haemophilus
influenza (𝑛 = 9).Methods. CSF inflammatory parameters, including cytokines and chemokines, MMP-9, and nitric oxide synthase
activity, were assessed in a cohort of patients with BM from Burkina Faso. Results. Pneumococcal meningitis was associated with
significantly higher CSF concentrations of IFN-𝛾, MCP-1, and the matrix-metalloproteinase (MMP-) 9. In patients with a fatal
outcome, levels of TNF-𝛼, IL-1𝛽, IL-1RA, IL-6, and TGF-𝛼 were significantly higher. Conclusion. The signature of pro- and anti-
inflammatory mediators and the intensity of inflammatory processes in CSF are determined by the bacterial pathogen causing
bacterial meningitis with pneumococcal meningitis being associated with a higher case fatality rate than meningitis caused by N.
meningitidis or H. influenzae.
1. Introduction
The threemajor pathogens causing bacterialmeningitis (BM)
are Streptococcus pneumoniae (SP), Haemophilus influenzae
type b (Hib) and Neisseria meningitidis (NM). BM is the
most severe and frequent infection of the central nervous
system (CNS) and is associated with a highmortality rate and
adverse neurological outcome in a substantial proportion of
survivors [1]. BM caused by SP has the highest case fatality
and neurological disability rates compared to those caused by
NM or Hib [2, 3]. In a recent systematic review, the median
inhospital case fatality ratio amongAfrican children with BM
was 35% for SP, 25% forHib, and 4% forNMmeningitis [4]. In
addition, about a quarter of children surviving pneumococ-
cal meningitis and Hib meningitis had neuropsychological
sequelae by the time of hospital discharge.
A number of factors have been identified as predictive
for a poor outcome in terms of mortality. Coma and seizures
were found to be predictive, next to shock, peripheral circula-
tory failure, severe respiratory distress, a low peripheral white
blood cell (WBC) count, and a high CSF protein level in a
recent systematic review of prognostic studies [5].
The host inflammatory reaction in the CNS is initiated
by the recognition of the invading pathogens and results
in the local production of soluble mediators. Differences ins
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2 Mediators of Inflammation
the innate immune responses upon stimulation with Gram-
positive andGram-negative bacteria have been demonstrated
in vitro and in experimental infection models. These differ-
ences are presumably related to pathogen-specific activation
of pattern recognition receptors [6–9]. Brain cells, that is,
astrocytes, microglial cells, endothelial cells, ependymal cells,
and resident macrophages, react to the invading pathogens
by releasing early response inflammatory cytokines, like IL-
1𝛽, TNF-𝛼, and IL-6. TNF-𝛼 stimulates the recruitment of
neutrophils and monocytes to the sites of infection and
activates these cells to eliminate pathogens, by releasing
reactive molecules, amongst others NO. Antibiotics causing
rapid lysis of the bacteria have been shown to exacerbate CSF
inflammation by increasing TNF-𝛼 [10]. After stimulation
by bacterial wall components or TNF-𝛼, IL-1𝛽 is released
by mononuclear phagocytes, glial cells, and endothelial cells.
High CSF level of IL-1𝛽 significantly correlates with adverse
outcome and severity of BM [11]. Administration of TNF-𝛼
or IL-1𝛽 into the CSF results in pathophysiological changes
characteristic of BM [12, 13]. IL-6 is produced by monocytes,
endothelial cells, and astrocytes, mainly in response to IL-1𝛽
[14]. IL-10 and IL-1RA antagonize the effect of proinflamma-
tory cytokines or chemokines, by inhibiting their production
(IL-10) or acting as a decoy receptor (IL-1RA). CSF levels of
other cytokines and chemokines (IL-2, IL-8, IFN-𝛾, MCP-1,
MIP-1, and G-CSF) have also been found elevated in BM [15–
19]. White blood cells invading the CSF release MMPs and
reactivemolecules [20–22]which are critically involved in the
pathogenesis of brain damage in BM. Therapeutic strategies
targetingMMPs and oxidative radical have yielded promising
results, albeit limited to experimental BM models [20–24]
to date. Tissue-destructive agents released by leukocytes and
brain resident cells, like matrix-metalloproteinases (MMPs)
and oxidants, also mediate brain damage in BM [22]. In BM,
MMPs are involved in the blood-brain barrier opening, in
immune cell extravasation, in the release of cytokines and
cytokine receptors, and in the development of neuronal dam-
age. In patients, elevated CSF levels of MMP-9 and MMP-8
have been detected [21], and high levels ofMMP-9 were iden-
tified as a risk factor for sequelae [25]. Nitric oxide (NO) has
been shown to contribute to the pathophysiology of menin-
gitis with a phase-dependent role at the level of the cerebral
vasculature by hyperemic effects in early phase and vasodila-
tive effects protecting against ischemia in later phase [26].
Since all of the above-detailed inflammatory mediators
have been shown to influence the outcome in experimental
models of BM, we set out to determine in patients with BM
the association between theCSF concentration of thesemedi-
ators with the causative organism and the mortality. To this
end the pathogen-specific inflammatory profiles caused by S.
pneumoniae,N.meningitidis, andH. influenzaewere analyzed
in CSF from BM patients. The findings from this study may
help understand, at a pathophysiological level, the difference
in outcome observed between the different pathogens.
2. Materials and Methods
2.1. CSF Samples. CSF samples were collected in the Nouna
HealthDistrict (NHD), Burkina Faso, during two consecutive
meningitis seasons [27]. Ethical clearance for the meningitis
study was obtained from the “Comite Local d’Ethique de
Nouna” (Nouna Local Ethical Committee). Procedures fol-
lowed were in accordance with the ethical standards of the
committee and with the Helsinki Declaration of the World
Medical Association. Informed consent was obtained from
all study participants. Following the national guidelines for
meningitis surveillance, diagnostic lumbar puncture was per-
formed on patients with a suspicion of meningitis presenting
to one of the 25 health centers of the NHD. Patients were
enrolled into the study if their CSF could be transported on
ice and analyzed by trained personnel in the laboratory of
NounaDistrictHospital within 6 hours. For primary analysis,
white blood cell counts were determined. Samples were tested
for bacterial pathogens using Gram staining, culture, latex
agglutination, or PCR. CSF samples were centrifuged to
remove white blood cells and supernatants stored at −80∘C.
Samples with conflicting diagnostics for the etiological agent
between culture and PCR were excluded from the analysis.
During transport from Africa to Switzerland, samples were
kept frozen in liquid nitrogen.
CSF samples with confirmed acute BM (positive cul-
ture and/or positive PCR, CSF WBC of more than 50∗106
cells/liter) were categorized into three analytical groups
according to the causative agent: S. pneumoniae (SP, 𝑛 = 14),
N. meningitidis (NM, 𝑛 = 22), and H. influenzae type b (Hib,
𝑛 = 9).
2.2. Assessment of Cytokine Levels in CSF Samples. Cytokine
levels in CSF samples were assessed using microsphere-
based multiplex assays (Lincoplex, LINCO Research Inc.,
St. Charles, MA, USA). CSF concentrations of the following
cytokines were measured: IL-1𝛼, IL-1𝛽, IL-2, IL-6, IL-8, IL-
10, IL-1RA, IFN-𝛾, MCP-1, MIP-1𝛼, MIP-1𝛽, TGF-𝛼, and
TNF-𝛼. To fit the dynamic range of the test, samples were
assessed undiluted or diluted 5- to 25-fold with the provided
assay buffer, depending on the expected concentration of the
respective analytes to be tested, as determined in preliminary
experiments. A minimum of 50 beads per analyte was
measured. Calibration curves from the provided standards
were calculated using BioPlex Manager software version 4.1.1
with a five-parametric logistic curve fitting. When measured
cytokine concentrations were below the detection limit, a
value corresponding to the detection limit of the assay
multiplied by the dilution factor of the sample was used for
statistical analysis.
Validation of the assay was done for IL-10 and TNF-𝛼
using Enzyme-linked immunosorbent assays (ELISA) (R&D
Systems Inc., Minneapolis, MN, USA). According to the
concentrations estimated using the Lincoplex assay and the
sensitivity range of the ELISA, samples were diluted 10-
fold (TNF-𝛼) or 20-fold (IL-10) to a final volume of 200 𝜇L
using the appropriate calibrator diluent. Results obtained
by Luminex and conventional ELISA were compared for
correlation, using Prism Software. For both cytokines, a
significant correlation was found between the two methods
(TNF-𝛼, 𝑃 = 0.002, Spearman 𝑟 = 0.53; IL-10, 𝑃 < 0.0001,
Spearman 𝑟 = 0.75).
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2.3. Assessment of MMP-9 Levels in CSF Samples. MMP-9
levels were assessed using the FluorokineMAPHumanMMP
Kit (R&D Systems Inc., Minneapolis, MN, USA). All CSF
samples were diluted 100-fold, to a final volume of 50 𝜇L. A
minimum of 50 beads was measured. Standard curves were
calculated similarly to those of the cytokines assay.
Validation of the assay was done using gelatin-containing
gel zymography as already described [21]. Concentrations
measured by the FluorokineMAP assay correlated with those
assessed by gelatin zymography with a two-tailed 𝑃-value of
<0.0001 (Spearman’s rank correlation test, 𝑟 = 0.66).
2.4. Measurement of Total Nitrate and Nitrite in CSF Samples.
CSF levels of total nitrate and nitrite were assessed using a
nitrate/nitrite colorimetric assay (Cayman Chemical Com-
pany, Ann Arbor, MI, USA). The estimated concentrations
were used as an index for nitric oxide synthase activity. CSF
samples were filtered for 30min at 10000 g using Ultrafree
−0.5 centrifugal filter devices. Samples and assay buffer (each
40 𝜇L) were mixed with 10 𝜇L of coenzyme mixture and
10 𝜇L of nitrate reductase in a 96-well plate. After 3 h at
room temperature (RT) for conversion of nitrate to nitrite,
Griess reagents were added for 10min at RT. Absorbance was
measured at 550 nm. Total nitrite concentrations were calcu-
lated using standard curves generated by the SoftMax PRO
software version 3.1.2 (Molecular Devices Inc., Sunnyvale,
CA, USA) using a linear curve fitting.
2.5. Statistical Analysis. Statistical analysis was done using
GraphPad Prism version 5.04 (GraphPad Software Inc., La
Jolla, CA, USA). For comparison of the different pathogen
groups, we first tested whether data sets followed a Gaussian
distribution. At least one group did not follow a Gaussian
distribution for each comparison. Furthermore, since we had
to include arbitrary values, the nonparametric Kruskal-Wallis
test was used. If the overall test was significant (𝑃 < 0.05), the
Mann-Whitney test was applied to perform pairwise compar-
isons. For the analysis of the relation between CSF cytokine
levels and the outcome of the disease, the nonparametric
Mann-Whitney test was used, with a confidence interval of
95% and two-tailed 𝑃 values. Correlations were analyzed
using Spearman’s rank correlation test, with a confidence
interval of 95% and two-tailed 𝑃 values.
3. Results
3.1. Clinical Parameters. Significant pathogen-specific differ-
ences in the age distribution of patients were observed within
the study cohort (𝑃 Kruskal-Wallis test: 𝑃 < 0.01). NM
meningitis was found in patients 0–60 years (median: 5.5
years, 𝑛 = 22) and SP meningitis in patients 0–40 years
(median: 5.5 years, 𝑛 = 14). In contrast, Hib meningitis
affected only children 1–4 years (median: 2 years, 𝑛 = 9). The
difference in median ages was significant between SP versus
Hib (𝑃 < 0.05) and NM versus Hib (𝑃 < 0.01). Mortality of
BM patients was 46% for SP and 27% for NM, while all nine
patients infected with Hib survived (Table 1).
CSF white blood cell counts did not significantly dif-
fer within the 3 groups (median SP: 7020× 106/L [100–
64000]; median NM: 4900× 106/L [100–38560]; median Hib:
5540× 106/L [272–20000]) (Table 2).
3.2. Cytokine and Chemokine Levels in CSF. Cytokines
and chemokines showed significantly different regulations
between the causative bacteria (Table 2 and Figure 1). In
particular, the CSF concentration of IFN-𝛾 was significantly
higher in patients infected with SP compared to NM (𝑃 <
0.005) and Hib (𝑃 < 0.005). The CSF concentration of IFN-𝛾
correlated with the age of the patients (𝑃 = 0.15, Pearson’s 𝑟 =
0.38; Figure 2).This correlationwas significant formeningitis
caused by SP (𝑃 = 0.01, 𝑟 = 0.79) and NM (𝑃 = 0.02,
𝑟 = 0.64). This suggests that, during meningitis, adults are
more apt to react with IFN-𝛾 production than children [28].
Since there was a statistically significant difference in age for
the Hib group, we cannot exclude that the difference in IFN-
𝛾 level in this population may be due to the age, rather than
the pathogen. For MCP-1 significant differences between SP
versus NM patients (𝑃 = 0.045) and SP versus Hib patients
(𝑃 < 0.01) were observed (Table 2). In addition, a nonsignifi-
cant trend for SP causing higher levels of IL-1𝛽 (𝑃 < 0.07) and
IL-6 (𝑃 = 0.055) was found. Taken together, reciprocal trends
in the association of pro- and anti-inflammatory cytokines
and chemokines with BM caused by the different pathogens
were observed. Il-1𝛽, IFN-𝛾, and MCP-1, as prototypical
proinflammatory factors, showed higher CSF concentrations
in the patients infected with SP than by NM and Hib. In
contrast, the anti-inflammatory mediators IL-10 and IL-1RA,
weremore increased in CSF of patients infected withNMand
Hib.The ratio of pro- to anti-inflammatorymediators, in par-
ticular the IL-1𝛽/IL-1RA ratio, showed statistically significant
differences, being higher in SP versus NM (𝑃 < 0.01) and SP
versus Hib (𝑃 < 0.03). Similar correlations were found for IL-
6/IL-10 and IL-6/IL-1RA ratios (Figure 3). Cyto-/chemokines
concentrations were significantly higher in patients infected
with any of the 3 pathogens when compared with a group
of 7 healthy control patients, as defined by no clinical signs
of meningitis and no increase in WBC in the CSF (median
4× 106 cells/L). For IL-1𝛽, IL-2, TNF𝛼, IFN𝛾, andMIP1 𝛼, the
majority of these samples were under detection limit, even
when samples were analyzed undiluted (Table 3).
Since the host inflammatory reaction during BM is an
important determinant of disease severity and mortality,
the association between CSF cytokine and chemokine levels
and outcome (survival or death) was investigated (Table 4(a)
and Figure 4). When all patients were analyzed together, a
significant association between fatal outcome and CSF levels
of 5 cytokines, namely, IL-1𝛽, TNF-𝛼, IL-1RA, IL-6 (𝑃 <
0.05), and TGF-𝛼 (𝑃 < 0.02), was found. When pathogens
were investigated separately, TNF-𝛼 was significantly higher
in patients who died from SP meningitis (Table 4(b)), while
only IL-1RA was significantly higher in patients with a fatal
outcome after NMmeningitis (Table 4(c)).
3.3. MMP-9, Nitrate and Nitrite Levels in CSF. In chil-
dren with bacterial meningitis, matrix-metalloproteinase-
(MMP-) 9 in the cerebrospinal fluid has been associated with
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Table 1: Patient groups characteristics.
Pathogen Number of patients Gender(male/female)
Median age
(min–max)
Mortality (%)
(survivors/death)
S. pneumoniae 14 5/81 5.5 (0–40) 46% (7/6)1
N. meningitidis 22 10/92 5.5 (1–60) 27% (16/6)
H. influenzae 9 7/2 2 (1–4) 0% (9/0)
11 patient not documented.
23 patients not documented.
Table 2: CSF inflammatory parameters of patients infected with SP (𝑛 = 14), NM (𝑛 = 22), and Hib (𝑛 = 9).
Streptococcus pneumoniae Neisseria meningitidis Haemophilus influenzae
𝑃 Kruskal-Wallis Between group
significanceMedian (min.–max.)
(pg/mL)
Median (min.–max.)
(pg/mL)
Median (min.–max.)
(pg/mL)
IL-1𝛽 116.2 (1.79–1040) 23.01 (0.61–325.9) 13.3 (0.77–112.5) 0.069 (b)
IL-2 3.28 (0.38–19.81) 1.41 (0.38–25.69) 1.6 (0.18–3.83) ns
IL-6 106232 (4440–175553) 93316 (5917–162002) 23257 (3917–112594) 0.0551 (b)
IL-10 7515 (509.5–44609) 18604 (1883–217931) 12692 (1466–135980) ns
IL-1RA 103123 (4413–983243) 243089 (3183–639929) 216530 (7712–1301000) ns
TNF-𝛼 233.8 (34.85–1199) 318.2 (17.6–3390) 170.3 (43.63–1395) ns
IFN-𝛾 58.99 (8.03–2853) 8.94 (1.77–219.8) 8.62 (0.42–20.03) <0.01 (a), (b)
MCP-1 10109 (1691–23567) 1896 (309.8–40005) 2059 (411.4–3897) <0.04 (a), (b)
MIP-1𝛼 829.1 (30.75–3828) 1469 (133.8–27027) 1152 (135.6–12782) ns
MIP-1𝛽 3344 (575.8–7518) 3263 (530.7–90852) 2563 (1364–22695) ns
TGF-𝛼 73.4 (16.36–302.3) 65.26 (10.3–146.5) 43.23 (27.52–305.2) ns
MMP-9 1.51 × 106 (275632–4.5 × 106) 525821 (1877–5.32 × 106) 334058 (12440–2.006 × 106) <0.03 (a), (b)
WBC 7020 (100–64000) 4900 (100–38560) 5540 (272–20000) ns
Nitrite/nitrate∗ 19.8 (9.5–104) 37 (19.24–124.1) 21.36 (4.533–41.5) 0.059 (c)
The nitrite/nitrate concentration (NO) was determined in a subset of CSFs, due to limitations in the available sample volumes (Hib 𝑛 = 8, SP = 8, and NM =
12).The column entitled “Between group significance” describes statistical significance between groups as determined byMann-Whitney test, for the following
comparisons (a) SP versus NM, (b) SP versus Hib, and (c) NM versus Hib.
Table 3: CSF inflammatory parameters in control patients (𝑛 = 7).
Analytes Samples under detection limit Median (pg/mL)[min.–max.] Dilution factor Detection limit
IL-1𝛽 5/7 n.d 1 : 1 0.19
IL-2 7/7 n.d. 1 : 1 0.38
IL-6 0/7 115 [95.06–175.1] 1 : 1 0.79
IL-10 1/7 39.96 [0.41–291.3] 1 : 1 0.41
IL-1RA 0/7 184.6 [99.82–2958] 1 : 1 10.76
TNF-𝛼 4/7 n.d 1 : 1 0.22
IFN-𝛾 7/7 n.d 1 : 1 0.55
MCP-1 0/7 326 [116–11355] 1 : 5 0.63
MIP-1𝛼 2/7 35.43 [1.23–536.6] 1 : 1 1.23
MIP-1𝛽 4/7 n.d 1 : 1 27.65
TGF-𝛼 0/7 24.16 [13.77–30.3] 1 : 1 0.69
MMP-9 0/7 106.8 [10.93–1153] 1 : 10 n.d.
A median value was calculated only when the majority of samples were above the limit of detection. Control samples were measured undiluted or diluted 1 : 5,
respectively, 1 : 10.
1Detection limit as provided by the manufacturer.
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Figure 1: Inflammatory CSF parameters in BM patients. Statistically significant differences ( ∗𝑃 < 0.05; ∗∗𝑃 < 0.01) in CSF concentrations
of MCP-1, IFN-𝛾, and MMP-9 were observed in patients with BM grouped for the causative pathogens.
blood-brain barrier damage and neurological sequelae [25].
Concentrations of MMP-9 were highest in CSF of patients
suffering from SPmeningitis (𝑃 < 0.03; Table 1 and Figure 1).
Pairwise comparisons between the different etiological agents
revealed SP versus Hib to differ significantly (𝑃 < 0.02) as
well as SP versus NM (𝑃 < 0.04) (Figure 1). MMP-9 showed
a nonsignificant trend towards higher CSF levels in patients
who died from the disease (Mann-Whitney test: 𝑃 = 0.068,
Table 4(a)).
Levels of total nitrate and nitrite showed a nonsignificant
trend (𝑃 ≤ 0.06) between pathogens, with higher CSF
concentrations in samples of NM patients than in SP andHib
patients (Table 1).
4. Discussion
In addition to the high mortality of up to 30%, cases of
BM and specifically those caused by SP are associated with
persistent neurological sequelae in up to 50% of the survivors
due to different forms of brain damage [29, 30]. The burden
of disease is especially high in low-income countries, and risk
of mortality or major sequelae is twice as high in African as
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Figure 2: Correlation between CSF levels of IFN-𝛾 and age of the patients. (a)The level of IFN-𝛾 correlated with the age of the patients. This
correlation was significant for SP patients ((b): 𝑃 = 0.01, 𝑟 = 0.79, and black dots) and NM patients ((c): 𝑃 = 0.02, 𝑟 = 0.64, and grey dots).
in the European regions [31]. Over the last four decades, the
risk ofmajor postdischarge sequelae caused bymeningitis has
not significantly changed [31]. Both clinical and experimental
studies suggest that both the pathogen and the inflammatory
host response contribute to the development of mortality and
neurological sequelae.
Here we compared the host immune response in the
CSF to BM caused by S. pneumoniae, N. meningitidis, and
H. influenzae. To date, only few studies have compared the
CSF concentration of inflammatory mediators during BM
in relation to the bacterial pathogen [17, 28, 32]. Here we
found that the pathogen is an important determinant of
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Figure 3: Ratio of pro- to anti-inflammatory mediators. Statistically significant differences ( ∗𝑃 < 0.05) in the ratios of IL-1𝛽/IL-1RA, IL-
6/IL-10, and IL-6/IL-1RA were observed in patients with BM grouped for the causative pathogens.
the inflammatory CSF reaction to BM. The observed differ-
ence in inflammation in the CSF may not only be due to
inherent differences between pathogens to elicit a response in
cells of the innate immune system [6–9] but also due to the
ability of the pathogen to multiply in the CNS compartment.
Unfortunately, determining the bacterial load in the CSF of
patients was not feasible in the present study.
In accordance with published data [17, 28], we observed
significantly higher CSF concentration of IFN-𝛾 in pneu-
mococcal meningitis. Furthermore, as observed by others,
the level of IFN-𝛾 correlated with the age of the patients.
This suggests that, during meningitis, adults are more apt to
react with IFN-𝛾 production than children [28]. IFN-𝛾 is a
potent proinflammatory cytokine. It enhances the function
of macrophages and polymorphonuclear leukocytes by stim-
ulating nonspecific defensemechanisms such as phagocytosis
and the release of inflammatory mediators andmay therefore
contribute to the overshooting inflammation.
We found elevated levels of the chemokinesMCP-1, MIP-
1𝛼, andMIP-1𝛽 in the CSF of patients with BM, in accordance
with other published studies [18, 19, 33]. CSF concentrations
of MCP-1 were significantly higher in patients infected with
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Figure 4: Significant differences in cytokines CSF levels in relation to disease outcome. Patients were grouped independently of the etiological
agents based on the outcome (nonlethal, white boxes/lethal, grey boxes) of the disease. Pairwise comparisons (Mann-Whitney test) revealed
statistically significant differences for the 5 cytokines (see also Table 4).
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Table 4: Difference in CSF inflammatory parameters between patients with a nonfatal and a fatal outcome.
(a) Pooled pathogens
Nonfatal cases Fatal cases Mann-Whitney
Median (min.–max.) (pg/mL) Median (min.–max.) (pg/mL)
IL-1𝛽 13.19 (0.61–1040) 57.19 (9.84–682) 0.046
IL-2 1.6 (0.18–255.69) 1.41 (0.38–6.9) 0.6618
IL-6 67789 (3917–162002) 104035 (77100–175553) 0.0365
IL-10 15764 (509.5–217931) 14131 (809–90755) 0.9351s
IL-1RA 117918 (3183–1.301 × 106) 337610 (19362–983243) 0.0209
TNF-𝛼 195.1 (17.6–3390) 484.3 (88.41–1199) 0.0436
IFN-𝛾 11.16 (0.42–1920) 49.13 (1.77–2853) 0.1823
MCP-1 2101 (309.8–40005) 2903 (1187–20728) 0.2193
MIP-1𝛼 935.6 (133.8–27027) 1166 (30.75–16122) 0.9351
MIP-1𝛽 2728 (530.7–24661) 3555 (1263–90852) 0.4177
TGF-𝛼 41.05 (10.30–305.2) 93.3 (36.74–302.3) 0.0099
MMP-9 463489 (1877–5.319 × 106) 1.258 × 106 (313541–4.497 × 106) 0.0671
WBC 4600 (100–186000) 11100 (1000–42400) 0.062
Nitrite/nitrate∗ 137.5 (23.15–625) 226.9 (83.6–368.5) 0.3627
(b) SP only
Non-fatal cases (𝑛 = 7) Fatal cases (𝑛 = 5) Mann-Whitney
Median (min.–max.) (pg/mL) Median (min.–max.) (pg/mL)
IL-1𝛽 54.44 (1.79–1040) 206.9 (9.84–682) 0.5253
IL-2 7.87 (0.38–19.81) 1.6 (0.38–5.55) 0.1452
IL-6 106232 (4440–150456) 136215 (77100–175553) 0.3434
IL-10 7515 (509.5–44609) 7497 (809–17392) 0.6010
IL-1RA 55240 (4413–275000) 121576 (19362–983243) 0.1591
TNF-𝛼 70.65 (0.22–570.9) 416.2 (88.41–1199) 0.048
IFN-𝛾 40.82 (8.03–1920) 190.7 (23.73–2853) 0.202
MCP-1 10109 (1691–23059) 2897 (2020–20307) 0.8207
MIP-1𝛼 829.1 (256.9–3828) 416.4 (30.75–1738) 0.5025
MIP-1𝛽 2732 (575.8–6685) 3771 (1263–7342) 0.6313
TGF-𝛼 35.52 (16.36–153.5) 100.5 (36.74–302.3) 0.149
MMP-9 1.103 × 106 (275632–4.254 × 106) 2.676 × 106 (475112–4.497 × 106) 0.2331
WBC 4600 (100–64000) 12930 (3200–42400) 0.1375
(c) NM only
Non-fatal cases (𝑛 = 15) Fatal cases (𝑛 = 5) Mann-Whitney
Median (min.–max.) (pg/mL) Median (min.–max.) (pg/mL)
IL-1𝛽 10.56 (0.61–325.9) 50.5 (10.48–205.4) 0.3056
IL-2 1.41 (0.38–25.69) 1.22 (0.38–6.9) 0.916
IL-6 67789 (5917–162002) 1100160 (77742–145357) 0.3056
IL-10 16715 (1883–217931) 47476 (5436–90755) 0.1974
IL-1RA 182057 (3183–305690) 447933 (275000–639929) 0.001
TNF-𝛼 267.2 (17.6–3390) 552.4 (247.4–1126) 0.2661
IFN-𝛾 9.1 (2.62–219.8) 8.3 (1.77–102.7) 0.5413
MCP-1 1283 (309.8–40005) 2909 (1187–20728) 0.3056
MIP-1𝛼 1200 (133.8–27027) 1937 (585.1–16122) 0.444
MIP-1𝛽 3137 (530.7–24661) 3388 (1851–90852) 0.5528
TGF-𝛼 44.05 (10.3–146.5) 86.05 (58.93–144.7) 0.0526
MMP-9 585934 (1877–5.319 × 106) 525821 (313541–2.188 × 106) 0.7996
WBC 4900 (100–17000) 7800 (1000–38560) 0.3983
Significantly higher CSF concentrations in patients with a fatal outcome are represented in italic lines.
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SP compared to both NM and Hib. Elevated CSF levels
of MCP-1 have been shown to exacerbate brain damage
during neuroinflammatory diseases by increasing the influx
of monocytes and neutrophils [34]. However, we did not find
a correlation of MCP-1 levels with WBCs in the CSF, which
is in accordance with other studies [18, 33]. Furthermore,
WBC count did not correlate with any other parameters,
either when pathogen groups were pooled together or when
analyzed separately. Worsening of the outcome by an over-
shooting inflammatory reaction is further suggested by the
increased ratios of pro- to anti-inflammatory mediators (IL-
6/IL-10, IL6/IL-1RA, and IL-1𝛽/IL-1RA) observed in patients
infected by SP. In a previous study in BM patients, CSF
showed higher ratio of TNF-𝛼/IL-10 by SP when compared
to NM and Hib combined [17].
High CSF concentration of MMP-9 is a risk factor for
a detrimental outcome [25, 35, 36]. Our results add further
support to the notion that MMP-9 is critically involved in the
increase inmortality and sequelae, sinceCSF levels ofMMP-9
were significantly higher in BM caused by SP, which is usually
associated with a higher incidence of neurological sequelae
and mortality [25].
When the relationship between inflammatory mediators
and the outcome of the disease was investigated indepen-
dently of the causative agent, higher CSF levels of TNF-
𝛼, IL-1𝛽, IL-1RA, IL-6, and TGF-𝛼 were found in patients
who died from BM. A nonsignificant trend was also found
for MMP-9 and IL-6. Thus, the present study confirms
previous observations showing that both a strong activation
of the IL-1𝛽 system [37] and increased MMP-9 levels [25]
correlate with adverse outcome of BM. While the higher
mortality observed in SP may be seen in the context of
higher cytokine levels, this observation could not be made
for the difference in mortality between NM (27%) and
Hib (0%) where inflammatory CSF parameters were not
significantly different. In comparison to other studies in
which mortality in developing regions reached 30% [38],
the mortality attributed to Hib was exceptionally low in the
present study.The small group size forHib is a clear limitation
of the study. Furthermore, NM meningitis is more often
associated with fulminant septicemia, which may contribute
to mortality. Unfortunately, data concerning the presence of
concomitant septicemia were not available in the present
study. Interestingly, the inhibition of the metalloproteinase
TACE/ADAM17, acting as a sheddase for TNF-𝛼 and TGF-
𝛼 [39], has been shown to lower mortality and to attenuate
brain injury in experimental models of BM [20, 36]. In line
with these results, we could show in the present study that
TNF-𝛼 was significantly upregulated in patients with a poor
outcome. In accordance with this clinical observation is the
experimental finding that deletion of another member of the
TGF family, TGF-𝛽 has been shown to improve bacterial
clearance and diminished intracranial complication in a
mouse with pneumococcal meningitis [40].
A nonsignificant trend for higher levels of nitrite/nitrate
levels was observed in NM infected patients. In experimental
models, CSF NO/nitrite concentration correlated with an
increase in blood-brain barrier permeability, but inhibition
of the different nitric oxide synthases resulted in inconsistent
effects, probably as a result of differences in the timing
of intervention and the corresponding effects on the brain
perfusion.
The present study, analyzing a cohort of patients affected
by meningitis, identified several factors which contribute
to the worsening of outcome in bacterial meningitis. Inter-
estingly, some of these factors (TNF-𝛼, MMPs, and nitric
oxide) have already been described in experimental models
using knockout animals [41] and/or intervention strategies
[42] which reduced mortality and ameliorated the outcome
of infected animals. The most promising strategies derived
from these experimental models include the reduction of
the inflammatory reaction by targeting different steps in the
inflammatory process [43], from the release of proinflam-
matory bacterial products to the activation of the innate
immune system and the production/release of cytokines or
chemokines, as well as the inhibition of metalloproteinases
or treatments with antioxidants [44].
5. Conclusion
In conclusion, this study showed that SP, NM, and Hib
elicit distinct profiles of inflammatory mediators in the
CSF during BM. A more intense inflammatory reaction, in
particular higher CSF levels of IFN-𝛾, MCP-1, and MMP-9,
were observed in patients infected with SP. Furthermore, the
ratios of pro- to anti-inflammatory parameters were found to
be significantly higher in patients with SP meningitis. This
is likely to contribute to the higher case fatality rate and
morbidity observed in patients suffering from pneumococcal
meningitis and may therefore help find new treatment strate-
gies aimed at improving the outcome of infected patients.
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